The ABSSSI claims on lie hub, drumming up the argument that IPIX should have moved forward with PIII trial clearly lacks the understanding that the ROI models turned cold by big Pharma with several acquisitions that have yet to pay off. It would have made zero sense to spend $30M minimum for PIII then hope for a big deal with big Pharma at the time. The business case didn't support moving B forward for ABSSSI. Anyone that says otherwise is a novice, amateur, child...lol. Interest is starting to pick up in ABSSSI again, but it's has a ways to go for supporting a decent ROI.